Print

Amgen (AMGN) Gets Priority Review For Prolia  
7/19/2010 6:53:42 AM

Pharma Times -- Amgen has received a boost with the news that regulators in the USA have granted a priority review to the company’s recently-approved denosumab, this time for the reduction of skeletal related events in advanced cancer patients.
//-->